Repositioning Candidate Details
| Candidate ID: | R1468 |
| Source ID: | DB12942 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Lactitol |
| Synonyms: | -- |
| Molecular Formula: | C12H24O11 |
| SMILES: | OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO |
| Structure: |
|
| DrugBank Description: | Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from . It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. ). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as , in the treatment of hepatic encephalopathy in patients with cirrhosis. Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020. |
| CAS Number: | 585-86-4 |
| Molecular Weight: | 344.3124 |
| DrugBank Indication: | Lactitol is indicated for the treatment of chronic idiopathic constipation in adults. |
| DrugBank Pharmacology: | Lactitol helps to facilitate bowel movements by drawing water into the gastrointestinal tract. The oral administration of lactitol may reduce the absorption of concomitant medications - other oral medications should be administered at least 2 hours before or 2 hours after lactitol. |
| DrugBank MoA: | Lactitol is an osmotic laxative - it exerts its pharmacologic effect by creating a hyperosmotic environment within the small intestine. The osmotic effect generated by lactitol draws water into the small intestine, which loosens stools and ultimately facilitates bowel movements. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|